Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norberto Perico

Showing results (171-180 of 202) with videos related to

Pageof 21
Sort By:
Plos One|March 7, 2012
Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort studyPiero Ruggenenti, Flavio Gaspari, Antonio Cannata, et al.
Lancet (London, England)|June 4, 2013
Kidney failure: aims for the next 10 years and barriers to successGiuseppe Remuzzi, Ariela Benigni, Fredric O Finkelstein, et al.
Pharmacological Research|March 17, 2024
Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: A literature systematic reviewMichelangela Barbieri, Paolo Chiodini, Piergiacomo Di Gennaro, et al.
Lancet (London, England)|August 11, 2004
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trialGiuseppe Remuzzi, Mariadomenica Lesti, Eliana Gotti, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|April 3, 2020
The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meetingMartin J Hoogduijn, Nuria Montserrat, Luc J W van der Laan, et al.
Lancet (London, England)|August 27, 2013
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trialAnna Caroli, Norberto Perico, Annalisa Perna, et al.
Kidney International Reports|June 20, 2024
Corrigendum to "An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKD" [<i>Kidney International Reports</i> Volume 9, Issue 2, February 2024, Pages 249-256]Jonathan Taylor, Richard Thomas, Peter Metherall, et al.
Kidney International Reports|February 12, 2024
An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKDJonathan Taylor, Richard Thomas, Peter Metherall, et al.
Plos Medicine|April 6, 2019
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trialNorberto Perico, Piero Ruggenenti, Annalisa Perna, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4Piero Ruggenenti, Giorgio Gentile, Norberto Perico, et al.
Pageof 21

Showing results (171-180 of 202) with videos related to

Sort By:
Pageof 21
Plos One|March 7, 2012
Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort studyPiero Ruggenenti, Flavio Gaspari, Antonio Cannata, et al.
Lancet (London, England)|June 4, 2013
Kidney failure: aims for the next 10 years and barriers to successGiuseppe Remuzzi, Ariela Benigni, Fredric O Finkelstein, et al.
Pharmacological Research|March 17, 2024
Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: A literature systematic reviewMichelangela Barbieri, Paolo Chiodini, Piergiacomo Di Gennaro, et al.
Lancet (London, England)|August 11, 2004
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trialGiuseppe Remuzzi, Mariadomenica Lesti, Eliana Gotti, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|April 3, 2020
The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meetingMartin J Hoogduijn, Nuria Montserrat, Luc J W van der Laan, et al.
Lancet (London, England)|August 27, 2013
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trialAnna Caroli, Norberto Perico, Annalisa Perna, et al.
Kidney International Reports|June 20, 2024
Corrigendum to "An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKD" [<i>Kidney International Reports</i> Volume 9, Issue 2, February 2024, Pages 249-256]Jonathan Taylor, Richard Thomas, Peter Metherall, et al.
Kidney International Reports|February 12, 2024
An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKDJonathan Taylor, Richard Thomas, Peter Metherall, et al.
Plos Medicine|April 6, 2019
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trialNorberto Perico, Piero Ruggenenti, Annalisa Perna, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4Piero Ruggenenti, Giorgio Gentile, Norberto Perico, et al.
Pageof 21